Use of antimicrobials in the treatment of febrile neutropenia in pediatric patients in a teaching hospital

Authors

DOI:

https://doi.org/10.30968/rbfhss.2023.144.0903

Abstract

Objectives: to assess the use of antimicrobials for the treatment of febrile neutropenia in pediatric patients Methods: a cross-sectional, retrospective and observational study carried out in the pediatric units of a large teaching hospital with high and medium complexity. All patients aged between 28 days and 17 years old, 11 months and 29 days old, who had febrile neutropenia and started a venous antimicrobials, were included in the study. Data were collected using available systems and compared with the sectoral clinical protocol. Results: 40 patients were included in the study, most of them male and with a median age of 8 years old. There were 70 episodes of neutropenia, and 57% were in disagreement with the protocol. The most common errors were the use of antimicrobials for longer than necessary, followed by de-escalation not performed after the culture result was available and antimicrobial incorrectly replaced. Considering the antimicrobials, the most prevalent was cefepime, and considering the antifungals, it was micafungin. Prescribed doses were in accordance with protocol, except for eight polymyxin loading dose prescriptions and one teicoplanin loading dose. Blood cultures were positive in 25.7% of cases and the most common microorganisms were Escherichia coli, Pseudomonas aeruginosa, Serratia marcescens,  Staphylococcus epidermidis, Staphylococcus  haemolyticus and Staphylococcus hominis. Conclusion: there were high rates of non-compliance in the  use of antimicrobials for the treatment of febrile neutropenia with the sectoral clinical protocol, despite the fact that most  prescriptions follow what is recommended when it comes to treatment initiation. It is essential to adapt the prescriptions to the institutional protocol  so that the patient receives an effective and safe treatment, avoiding the occurrence of bacterial resistance due to the inappropriate use of  medicines.

Downloads

Download data is not yet available.

References

Ahmed NM, Palazzi DL. Evaluation of children with non-chemotherapy-induced neutropenia and fever-UpToDate [Internet]. 2021. Available from: https://www.uptodate.com/contents/evaluation-of-children-with-non-chemotherapy-induced-neutropenia-and-fever?topicRef=6051&source=see_l

Kebudi R, Kizilocak H. Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment. Curr Pediatr Rev. 2018 Jun 22;14(3):204–9.

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Vol. 52, Clinical Infectious Diseases. Oxford University Press; 2011.

Frater JL. How I investigate neutropenia. Vol. 42, International Journal of Laboratory Hematology. Blackwell Publishing Ltd; 2020. p. 121–32.

Silva D, Barreto J, Córdoba J, et al. Diretrizes para o manejo inicial da neutropenia febril, após quimioterapia, em crianças e ado- lescentes com câncer. Departamento Científico de Oncologia. 2018.

Fernandes T. Atualização de condutas em pediatria. Socie- dade de Pediatria de São Paulo. 2019.

Febre em lactentes e crianças: Fisiopatologia e manejo [In- ternet]. 2022. Available from: https://www.uptodate.com/ contents/fever-in-infants-and-children-pathophysiology-and-management/print?search=definitionoffeverinchil dren&…1/31www.uptodate.com

Lehrnbecher T. Treatment of fever in neutropenia in pediatric oncology patients. Vol. 31, Current Opinion in Pediatrics. Lip- pincott Williams and Wilkins; 2019. p. 35–40.

Roseland J. Improving Antibiotic Timing in Febrile Neutrope- nia for Pediatric Oncology Patients with a Central Line. Journal of Pediatric Oncology Nursing. 2021 May 1;38(3):185–9.

Lehrnbecher T, Averbuch D, Castagnola E, et al. 8th Europe- an Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in pediatric patients with cancer or post-haematopoietic cell transplantation. Vol. 22, The Lancet Oncology. Lancet Publishing Group; 2021. p. e270–80.

Lehrnbecher T, Robinson P, Fisher B, et al. Journal Of Clinical Oncology Guideline for the Management of Fever and Neu- tropenia in Children With Cancer and Hematopoietic Stem- Cell Transplantation Recipients: 2017 Update. J Clin Oncol [Internet]. 2017;35:2082–94. Available from: https://doi. org/10.1200/JCO.2016.

Kebede HK, Gesesew HA, Woldehaimanot TE, et al. Antimi- crobial use in paediatric patients in a teaching hospital in Ethi- opia. PLoS One. 2017 Mar 1;12(3).

Religioni U, Pakulska T. Rational drug use in hospital set- tings–areas that can be changed. J Med Econ. 2020 Oct 2;23(10):1205–8.

Wang H, Wang H, Yu X, et al. Impact of antimicrobial stew- ardship managed by clinical pharmacists on antibiotic use and drug resistance in a Chinese hospital, 2010-2016: A retrospective observational study. BMJ Open. 2019 Aug 1;9(8).

Karandikar M v., Milliren CE, Zaboulian R, et al. Limiting van- comycin exposure in pediatric oncology patients with febrile neutropenia may be associated with decreased vancomycin-resistant enterococcus incidence. J Pediatric Infect Dis Soc. 2020;9(4):428–36.

Reinecke J, Lowas S, Snowden J, et al. Blood Stream Infections and Antibiotic Utilization in Pediatric Leukemia Patients With Febrile Neutropenia [Internet]. 2018. Available from: www.jpho-online.com

Yang J, Zheng L, Guan YY, et al. Drug and therapeutics committee interventions in managing irrational drug use and an- timicrobial stewardship in China. Front Pharmacol. 2022 Jul 22;13.

Machowska A, Lundborg CS. Drivers of irrational use of antibi- otics in Europe. Vol. 16, International Journal of Environmental Research and Public Health. MDPI AG; 2019.

Scheler M, Lehrnbecher T, Groll AH, et al. Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland. Infection. 2020 Aug 1;48(4):607–18.

Wu CT, Chen CL, Lee HY, et al. Decreased antimicrobial resistance and defined daily doses after implementation of a clinical culture-guided antimicrobial stewardship program in a local hospital. Journal of Microbiology, Immunology and Infection. 2017 Dec 1;50(6):846–56.

Sano H, Kobayashi R, Suzuki D, et al. A prospective random- ized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders. Pediatr Blood Cancer. 2017 Jun 1;64(6).

Rosanova MT, Cuellar-Pompa L, Lede R. Eficacia y seguridad del tratamiento empírico con piperacilina/tazobactan como monoterapia en episodios de neutropenia y fiebre en niños con cáncer: revisión sistemática y meta-análisis. Rev Chilena Infectol 2021; 38 (4): 488-494

Huemer M, Mairpady Shambat S, Brugger SD, et al. Antibiotic resistance and persistence—Implications for human health and treatment perspectives. EMBO Rep. 2020 Dec 3;21(12).

Yamashita C, Takesue Y, Matsumoto K, et al. Echinocandins versus non-echinocandins for empirical antifungal therapy in patients with hematological disease with febrile neutropenia: A systematic review and meta-analysis. Journal of Infection and Chemotherapy. 2020 Jun 1;26(6):596–603.

Chiotos K, Hayes M, Gerber JS, et al. Treatment of Carbapen- em-Resistant Enterobacteriaceae Infections in Children. Vol. 9, Journal of the Pediatric Infectious Diseases Society. Oxford University Press; 2019. p. 56–66.

Sathyapalan DT, James J, Sudhir S, et al. Antimicrobial stew- ardship and its impact on the changing epidemiology of poly- myxin use in a south indian healthcare setting. Antibiotics. 2021 May 1;10(5).

Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), Euro- pean Society of Clinical Microbiology and Infectious Diseas- es (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infec- tious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 Jan 1;39(1):10–39.

Pea F. Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. Vol. 26, Journal of Infection and Chemotherapy. Elsevier B.V.; 2020. p. 900–7.

Kim SH, Kang CI, Huh K, et al. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy. Euro- pean Journal of Clinical Microbiology and Infectious Diseases. 2019 Nov 1;38(11):2113–20.

Alali M, David MZ, Danziger-Isakov LA, et al. Pediatric Febrile Neutropenia: Change in Etiology of Bacteremia, Empiric Choice of Therapy and Clinical Outcomes [Internet]. 2020. Available from: www.jpho-online.com

MacMillan KM, MacInnis M, Fitzpatrick E, et al. Evaluation of a pharmacist-led antimicrobial stewardship service in a pe- diatric emergency department. Int J Clin Pharm. 2019 Dec 1;41(6):1592–8.

Pharm Sci PJ, Tian J, Wang MM, et al. Effect of pharmacist interventions on antibiotic use in the general pediatric ward. 2020;33(3):1389–95.

Parente DM, Morton J. Role of the Pharmacist in Antimicro- bial Stewardship. Vol. 102, Medical Clinics of North America. W.B. Saunders; 2018. p. 929–36.

Published

2024-01-08

How to Cite

1.
LIMA CS, SILVEIRA LP, ALVES SR, MENEZES RR, CHEMELLO C. Use of antimicrobials in the treatment of febrile neutropenia in pediatric patients in a teaching hospital. Rev Bras Farm Hosp Serv Saude [Internet]. 2024Jan.8 [cited 2024Feb.22];14(4):903. Available from: https://rbfhss.org.br/sbrafh/article/view/903

Issue

Section

ORIGINAL ARTICLES